## TB5

Cat. No.:	HY-100975		
CAS No.:	948841-07-4		
Molecular Formula:	C <sub>15</sub> H <sub>14</sub> BrNOS		
Molecular Weight:	336.25		
Target:	Monoamine Oxidase		
Pathway:	Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

R

MedChemExpress

## SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (29.74 mM; ultrasonic and	d warming and heat to 60°C)
---	-----------------------------

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.9740 mL	14.8699 mL	29.7398 mL
	5 mM	0.5948 mL	2.9740 mL	5.9480 mL
	10 mM	0.2974 mL	1.4870 mL	2.9740 mL

Please refer to the solubility information to select the appropriate solvent.

Description	TB5 is a potent, selective and reversible inhibitor of hMAO-B with a $K_{\rm i}$ value of 0.11±0.01 $\mu M.$	
IC <sub>50</sub> & Target	Ki: 0.11±0.01 μM (hMAO-B) <sup>[1]</sup>	
In Vitro	TB5 and TB8 interacts with the catalytic site of hMAO-B and hMAO-A with a competitive mode of inhibition. TB5 shows the best inhibitory activity and higher selectivity toward hMAO-B, with K <sub>i</sub> and SI values of 0.11±0.01μM and 13.18, respectively. hMAO-B inhibition by compound TB5 and hMAO-A inhibition by compound TB8 are completely reversed after 24 h of dialysis. Cytotoxicity studies show TB5 is nontoxic at 5 and 25 μM, resulting in cell viabilities of 95.75% and 84.59 %, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Compounds are dissolved in DMSO (5 mg/mL) and diluted with PBS/EtOH (70:30).Kinetic analyses are carried out for TB5 and TB8. A set of Lineweaver–Burk plots are constructed in the absence and presence of various concentrations of compounds TB5 and TC8. The set consists of five graphs, each constructed by measuring MAO-B and MAO-A catalytic rates at different substrate concentrations (0.1-1 µM). The first Lineweaver–Burk plot is constructed in the absence of inhibitor,	

## Product Data Sheet

while the remaining four graphs are constructed in the presence of different concentrations of TB5 and TB8 <sup>[1]</sup> .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL	
Kinase Assay <sup>[1]</sup>	Compounds are dissolved in DMSO (5 mg/mL) and diluted with PBS/EtOH (70:30).Kinetic analyses are carried out for TB5 and TB8. A set of Lineweaver–Burk plots are constructed in the absence and presence of various concentrations of compounds TB5 and TC8. The set consists of five graphs, each constructed by measuring MAO-B and MAO-A catalytic rates at different substrate concentrations (0.1-1 µM). The first Lineweaver–Burk plot is constructed in the absence of inhibitor, while the remaining four graphs are constructed in the presence of different concentrations of TB5 and TB8 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay <sup>[1]</sup>	In vitro cytotoxicity of brominated thiophene chalcones and standard MAO inhibitors are tested in human HepG2 hepatic cancer cells at three different concentrations (1, 5 and 25 μM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Mathew B, et al. Synthesis, Biochemistry, and Computational Studies of Brominated Thienyl Chalcones: A New Class of Reversible MAO-B Inhibitors. ChemMedChem. 2016 Jun 6;11(11):1161-71.

Caution: Product has not been fully validated for medical applications. For research use only.